Top-Rated StocksTop-RatedNASDAQ:KRYS Krystal Biotech (KRYS) Stock Price, News & Analysis $334.85 +12.57 (+3.90%) Closing price 10/5/2026 04:00 PM EasternExtended Trading$332.50 -2.35 (-0.70%) As of 10/5/2026 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Krystal Biotech Stock (NASDAQ:KRYS) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Krystal Biotech alerts:Sign Up Key Stats Today's Range$321.37▼$339.6950-Day Range$312.57▼$371.4752-Week Range$179.19▼$382.54Volume337,043 shsAverage Volume273,957 shsMarket Capitalization$9.91 billionP/E Ratio41.96Dividend YieldN/APrice Target$377.20Consensus RatingBuy Company Overview Krystal Biotech, Inc. is a biotechnology company focused on developing and commercializing genetic medicines for rare diseases. The company uses engineered herpes simplex virus type 1 (HSV-1) vectors designed to deliver functional genes to targeted tissues, with the goal of treating diseases caused by genetic mutations. Krystal Biotech’s lead product, VYJUVEK (beremagene geperpavec-svdt), is a topical gene therapy approved in the United States for the treatment of wounds in patients with dystrophic epidermolysis bullosa, a rare inherited disorder that causes fragile skin and recurrent blistering. VYJUVEK is designed for repeated application to wounds and became the first commercially available treatment based on the company’s HSV-1 gene-delivery platform. Founded in 2015 and headquartered in Pittsburgh, Pennsylvania, Krystal Biotech conducts research, clinical development and commercialization activities in the United States and other international markets. The company continues to evaluate its platform for additional rare diseases, including conditions affecting the skin, lungs and other tissues. Krystal Biotech is led by co-founder Krish S. Krishnan, who serves as chairman and chief executive officer.AI Generated. May Contain Errors. Read More Krystal Biotech Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks86th Percentile Overall ScoreKRYS MarketRank™: Krystal Biotech scored higher than 86% of companies evaluated by MarketBeat, and ranked 100th out of 888 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingKrystal Biotech has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 strong buy ratings, 10 buy ratings, 2 hold ratings, and no sell ratings.Upside PotentialKrystal Biotech has a consensus price target of $377.20, representing about 12.6% upside from its current price of $334.85.Amount of Analyst CoverageKrystal Biotech has been the subject of 8 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Krystal Biotech's stock forecast and price target. Earnings and Valuation3.1 / 5Proj. Earnings Growth22.46% Earnings GrowthEarnings for Krystal Biotech are expected to grow by 22.46% in the coming year, from $7.48 to $9.16 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Krystal Biotech is 41.96, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 44.65.Price to Earnings Ratio vs. SectorThe P/E ratio of Krystal Biotech is 41.96, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 274.32.Price to Book Value per Share RatioKrystal Biotech has a P/B Ratio of 7.96. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Krystal Biotech's valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted12.30% of the float of Krystal Biotech has been sold short.Short Interest Ratio / Days to CoverKrystal Biotech has a short interest ratio ("days to cover") of 13.23, which indicates bearish sentiment.Change versus previous monthShort interest in Krystal Biotech has recently decreased by 5.50%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldKrystal Biotech does not currently pay a dividend.Dividend GrowthKrystal Biotech does not have a long track record of dividend growth. News and Social Media3.6 / 5News SentimentN/A News SentimentKrystal Biotech has a news sentiment score of 0.76. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.43 average news sentiment score of Healthcare companies.Search Interest10 people have searched for KRYS on MarketBeat in the last 30 days. This is an increase of 400% compared to the previous 30 days.MarketBeat Follows5 people have added Krystal Biotech to their MarketBeat watchlist in the last 30 days. This is an increase of 67% compared to the previous 30 days. Company Ownership1.9 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Krystal Biotech insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $17,211,000.00 in company stock.Percentage Held by Insiders13.10% of the stock of Krystal Biotech is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions86.29% of the stock of Krystal Biotech is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Krystal Biotech's insider trading history. Receive KRYS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Krystal Biotech and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. KRYS Stock News HeadlinesKrystal Biotech (KRYS) Has a Blockbuster Rare-Disease Drug. Is Its Moat Durable?55 minutes ago | insidermonkey.comKrystal Biotech (NASDAQ:KRYS) Research Coverage Started at The Goldman Sachs GroupSeptember 27, 2026 | americanbankingnews.comMan who Predicted Trump 2016 Win: “Prepare for Mid-Term Meltdown”In 2016, major election models gave Hillary Clinton a 99% chance of winning - but former CIA and Pentagon adviser Jim Rickards publicly predicted a Trump victory before election night. Now Rickards is issuing a new forecast he calls a potential mid-term meltdown, one he believes could send shockwaves through financial markets. | Paradigm Press (Ad)Goldman Sachs Resumes Coverage with a Buy Rating on Krystal Biotech (KRYS)September 26, 2026 | theglobeandmail.comBofA Adjusts Price Target on Krystal Biotech to $400 From $392, Keeps Buy RatingSeptember 21, 2026 | marketscreener.comMKrystal Biotech to Participate in 2026 Cantor Global Healthcare ConferenceSeptember 3, 2026 | quiverquant.comQKrystal Biotech to Present at 2026 Cantor Global Healthcare ConferenceSeptember 3, 2026 | globenewswire.comKrystal Biotech (KRYS) Has a New Rating from RBC CapitalAugust 17, 2026 | theglobeandmail.comSee More Headlines KRYS Stock Analysis - Frequently Asked Questions How have KRYS shares performed this year? Krystal Biotech's stock was trading at $246.54 at the beginning of the year. Since then, KRYS stock has increased by 35.8% and is now trading at $334.85. How were Krystal Biotech's earnings last quarter? Krystal Biotech, Inc. (NASDAQ:KRYS) announced its earnings results on Monday, August, 3rd. The company reported $1.79 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.70 by $0.09. The company earned $119.22 million during the quarter, compared to analyst estimates of $120.93 million. Krystal Biotech had a net margin of 54.82% and a trailing twelve-month return on equity of 19.34%. Read the conference call transcript. When did Krystal Biotech IPO? Krystal Biotech (KRYS) raised $40 million in an initial public offering (IPO) on Wednesday, September 20th 2017. The company issued 3,960,000 shares at $9.00-$11.00 per share. Ladenburg Thalmann acted as the underwriter for the IPO. How do I buy shares of Krystal Biotech? Shares of KRYS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Krystal Biotech own? Based on aggregate information from My MarketBeat watchlists, some other companies that Krystal Biotech investors own include Humana (HUM), American Water Works (AWK), Voyager Therapeutics (VYGR), Waste Connections (WCN), The RMR Group (RMR), DiamondRock Hospitality (DRH) and AUO (AUOTY). Company Calendar Last Earnings8/03/2026Today10/05/2026Next Earnings (Estimated)11/02/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (12m+) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 KRYS's financial health is in the Green zone, according to TradeSmith. KRYS has been in this zone for over 12 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:KRYS CIK1711279 Webwww.krystalbio.com Phone(412) 586-5830FaxN/AEmployees295Year Founded2017Price Target and Rating Average Price Target for Krystal Biotech$377.20 High Price Target$474.00 Low Price Target$284.00 Potential Upside/Downside+12.6%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage14 Analysts Profitability EPS (Trailing Twelve Months)$7.98 Trailing P/E Ratio41.96 Forward P/E Ratio44.77 P/E GrowthN/ANet Income$204.83 million Net Margins54.82% Pretax Margin51.45% Return on Equity19.34% Return on Assets17.65% Debt Debt-to-Equity RatioN/A Current Ratio8.32 Quick Ratio7.96 Sales & Book Value Annual Sales$440.48 million Price / Sales22.50 Cash Flow$7.57 per share Price / Cash Flow44.21 Book Value$42.06 per share Price / Book7.96Miscellaneous Outstanding Shares29,599,000Free Float25,722,000Market Cap$9.91 billion OptionableOptionable Beta0.50 Social Links 7 Blue-Chip Stocks to Add To Your Forever PortfolioA strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership. This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.Get This Free Report This page (NASDAQ:KRYS) was last updated on 10/6/2026 by MarketBeat.com Staff. From Our PartnersThis smart glasses tech is bringing the screen to your eyesGlobal AI smart-glasses shipments surged 263% in the first half of 2026, and Citi projects the market could re...The Tomorrow Investor | SponsoredTrump goes "all-in" on Grand Canyon energy breakthroughA drilling crew near the Grand Canyon uncovered a clean energy well producing nearly eight times the output of...Behind the Markets | SponsoredMusk says UBI is coming. I say it's already here.Elon Musk says AI could make money irrelevant by 2036. One income program already exists today, funded not by ...Freedom Financial | SponsoredSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...Altimetry | SponsoredMan who Predicted Trump 2016 Win: “Prepare for Mid-Term Meltdown”In 2016, major election models gave Hillary Clinton a 99% chance of winning - but former CIA and Pentagon advi...Paradigm Press | SponsoredI've seen this movie before (last time: 17,556%)My track record speaks for itself... KDA: 17,556%. PRE: 3,900%. OCEAN: 2,650%. Every single one was called ...Crypto 101 Media | SponsoredThe case for $20,000 gold before year endPresident Trump reposted a warning from precious metals expert Jim Rickards, tying the November midterms and A...Stansberry Research | SponsoredWhy major institutions are piling into this digital asset nowBlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...Awesomely | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Krystal Biotech, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Krystal Biotech With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
